Id: acc1444
Group: 2sens
Protein: ULK1
Gene Symbol: ULK1
Protein Id: O75385
Protein Name: ULK1_HUMAN
PTM: phosphorylation
Site: Ser467
Site Sequence: RSSAIRRSGSTSPLGFARASP
Disease Category: Cancer
Disease: Glioma
Disease Subtype:
Disease Cellline: U251?
Disease Info:
Drug: xanthatin
Drug Info: -
Effect: modulate
Effect Info: "Drugs kill tumors by increasing the phosphorylation of Akt (ser473), a downstream target of PI3K, and then directly activating mTORC1 through the phosphorylation of mTOR at the Ser2448 site, thereby reducing the level of phosphorylated ULK1."
Note:
Score: 4.0
Pubmed(PMID): 36572650
Sentence Index:
Sentence:

Sequence & Structure:

MEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHREKHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPSVRKSPPVPVPSYPSSGSGSSSSSSSTSHLASPPSLGEMQQLQKTLASPADTAGFLHSSRDSGGSKDSSCDTDDFVMVPAQFPGDLVAEAPSAKPPPDSLMCSGSSLVASAGLESHGRTPSPSPPCSSSPSPSGRAGPFSSSRCGASVPIPVPTQVQNYQRIERNLQSPTQFQTPRSSAIRRSGSTSPLGFARASPSPPAHAEHGGVLARKMSLGGGRPYTPSPQVGTIPERPGWSGTPSPQGAEMRGGRSPRPGSSAPEHSPRTSGLGCRLHSAPNLSDLHVVRPKLPKPPTDPLGAVFSPPQASPPQPSHGLQSCRNLRGSPKLPDFLQRNPLPPILGSPTKAVPSFDFPKTPSSQNLLALLARQGVVMTPPRNRTLPDLSEVGPFHGQPLGPGLRPGEDPKGPFGRSFSTSRLTDLLLKAAFGTQAPDPGSTESLQEKPMEIAPSAGFGGSLHPGARAGGTSSPSPVVFTVGSPPSGSTPPQGPRTRMFSAGPTGSASSSARHLVPGPCSEAPAPELPAPGHGCSFADPITANLEGAVTFEAPDLPEETLMEQEHTEILRGLRFTLLFVQHVLEIAALKGSASEAAGGPEYQLQESVVADQISLLSREWGFAEQLVLYLKVAELLSSGLQSAIDQIRAGKLCLSSTVKQVVRRLNELYKASVVSCQGLSLRLQRFFLDKQRLLDRIHSITAERLIFSHAVQMVQSAALDEMFQHREGCVPRYHKALLLLEGLQHMLSDQADIENVTKCKLCIERRLSALLTGICA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
ULK1-Ser467
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 556 D Psoriasis Phosphorylation 34421918
S 317 D Melanoma Phosphorylation 34759263
S 757 D Melanoma Phosphorylation 34759263
S 556 D Gastric cancer Phosphorylation 33037394
S 555 D Melanoma Phosphorylation 34759263
K 571 P Breast cancer Ubiquitination 35670107
S 757 P Non-small cell lung cancer/carcinoma Phosphorylation 23921130
K 568 P Breast cancer Ubiquitination 35670107
S 495 P Breast cancer Phosphorylation 35670107
S 495 U Glioma Phosphorylation 31378785
S 757 U Melanoma Phosphorylation 34759263
S 555 U Melanoma Phosphorylation 34759263
S 533 U Glioma Phosphorylation 31378785
K 68 U Acute liver failure Acetylation 33431796
S 469 U Glioma Phosphorylation 31378785
S 317 U Melanoma Phosphorylation 34759263
S 317 U Late onset Parkinson's disease Phosphorylation 35605642
S 555 U Granulomatosis with polyangiitis Phosphorylation 37720230

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
O75385 ULK1 P Ser467;Ser469 SGS(ph)TS(ph)PLGFAR A431 Afatinib 8.681 -
O75385 ULK1 P Ser467;Ser469 SGS(ph)TS(ph)PLGFAR A431 Gefitinib 9.1965 -
O75385 ULK1 P Ser467;Ser469 SGS(ph)TS(ph)PLGFAR BT-474 Lapatinib 6.0856 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: